Cellectar Biosciences (CLRB) Accounts Payables (2010 - 2026)
Cellectar Biosciences (CLRB) posted Accounts Payables of $4.4 million for Q4 2025, up 10.2% sequentially from $4.0 million in Q3 2025, and down 41.67% YoY from $7.6 million in Q4 2024.
Cellectar Biosciences (CLRB) Accounts Payables (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Accounts Payables for 16 years, with the latest figure at $4.4 million in Q4 2025.
- Quarterly Accounts Payables fell 41.67% year-over-year to $4.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.4 million (down 41.67% YoY) and the FY2025 annual result came in at $4.4 million, down 41.67% from the prior year.
- Accounts Payables grew to $4.4 million in Q4 2025 per CLRB's latest filing, from $4.0 million in the prior quarter.
- Over five years, Accounts Payables peaked at $9.2 million in Q4 2023 and troughed at $3.0 million in Q3 2021.
- A 5-year average of $5.7 million and a median of $5.5 million in 2022 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables soared 109.82% in 2022, then plunged 51.66% in 2025.
- Over 5 years, Accounts Payables stood at $3.9 million in 2021, then surged by 42.12% to $5.5 million in 2022, then jumped by 67.55% to $9.2 million in 2023, then decreased by 17.37% to $7.6 million in 2024, then slumped by 41.67% to $4.4 million in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $4.4 million, $4.0 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | 5.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.22 Mn |
| Dec 31, 2025 | 4.42 Mn |
| Sep 30, 2025 | 4.01 Mn |
| Jun 30, 2025 | 4.68 Mn |
| Mar 31, 2025 | 3.87 Mn |
| Dec 31, 2024 | 7.59 Mn |
| Sep 30, 2024 | 8.30 Mn |
| Jun 30, 2024 | 6.46 Mn |
| Mar 31, 2024 | 7.39 Mn |
| Dec 31, 2023 | 9.18 Mn |
| Sep 30, 2023 | 7.81 Mn |
| Jun 30, 2023 | 6.39 Mn |
| Mar 31, 2023 | 6.90 Mn |
| Dec 31, 2022 | 5.48 Mn |
| Sep 30, 2022 | 6.37 Mn |
| Jun 30, 2022 | 5.46 Mn |
| Mar 31, 2022 | 4.51 Mn |
| Dec 31, 2021 | 3.85 Mn |
| Sep 30, 2021 | 3.03 Mn |
| Jun 30, 2021 | 3.39 Mn |